Asterand Bioscience, the leader in high quality, well-characterized human...
Chris is a General Partner of Lightstone Ventures. He focuses on biopharmaceutical investments out of the firm’s Boulder, CO, office. Chris joined Morgenthaler in 2001 and serves as a General Partner. His signature deals include Avidia (acquired by Amgen in 2006), Threshold (NASDAQ: THLD), Morphotek (acquired by Easai in 2007), FoldRx (acquired by Pfizer in 2010), and Nimbus Therapeutics/Apollo (acquired by Gilead in 2015). He serves on the boards of Tragara Pharmaceuticals, Asterand, Elcelyx, and Nimbus. Chris brings to Lightstone more than 20 years of operations experience, having served as CEO and President of Ribozyme Pharmaceuticals (a/k/a Sirna Therapeutics; acquired by Merck for $1.2B), Senior Vice President of Research at SmithKline Beecham, Vice President of Discovery Research at The Upjohn Company, and President of Colorado State University.
Chris is a recognized thought leader in the field of biotechnology. He received an honorary doctor of law degree from Cornell College in 1983, the Outstanding Research of Year Award from the International Society of Quantum Biology in 1981, the W. E. Upjohn Award for contributions in biotechnology in 1988, and a Lifetime Achievement Award in 2003 from the Colorado Biosciences Association.
B.S. in Chemistry and Mathematics, Honorary J.D. from Cornell College
Ph.D. in Chemistry from Indiana University
02.15.17Asterand Bioscience and MolecularMD announce a partnership to accelerate targeted therapeutic biomarker validation, optimization, development and commercialization
11.01.16Nimbus Therapeutics Announces $200 Million Milestone Payment from Gilead Sciences for Allosteric ACC Inhibitor Program in Non-alcoholic Steatohepatitis (NASH)
11.01.16Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into PhII NASH trial